



## Clinical trial results:

### A Phase 1b, Open-Label, Single Dose Study Assessing the Pharmacokinetics, Safety, Tolerability, and Efficacy of Intravenous Anti-Spike(s) SARS-CoV-2 Monoclonal Antibodies (Casirivimab+Imdevimab) for the Treatment of Pediatric Patients Hospitalized Due to COVID-19

#### Summary

|                          |                |
|--------------------------|----------------|
| EudraCT number           | 2021-004535-84 |
| Trial protocol           | Outside EU/EEA |
| Global end of trial date | 28 June 2022   |

#### Results information

|                                |                  |
|--------------------------------|------------------|
| Result version number          | v1 (current)     |
| This version publication date  | 22 December 2022 |
| First version publication date | 22 December 2022 |

#### Trial information

##### Trial identification

|                       |                       |
|-----------------------|-----------------------|
| Sponsor protocol code | R10933-10987-COV-2114 |
|-----------------------|-----------------------|

##### Additional study identifiers

|                                    |             |
|------------------------------------|-------------|
| ISRCTN number                      | -           |
| ClinicalTrials.gov id (NCT number) | NCT05092581 |
| WHO universal trial number (UTN)   | -           |

Notes:

#### Sponsors

|                              |  |
|------------------------------|--|
| Sponsor organisation name    | Regeneron Pharmaceuticals, Inc   |
| Sponsor organisation address | 777 Old Saw Mill River Rd., Tarrytown, United States, 10591  |
| Public contact               | Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 8447346643, clinicaltrials@regeneron.com |
| Scientific contact           | Clinical Trial Management, Regeneron Pharmaceuticals, Inc, 001 8447346643, clinicaltrials@regeneron.com      |

Notes:

#### Paediatric regulatory details

|  |  |
|--|--|
| Is trial part of an agreed paediatric investigation plan (PIP)       | Yes                                      |
| EMA paediatric investigation plan number(s)                          | EMA-002965-PIP01-21, EMA-002964-PIP01-21 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No                                       |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes                                      |

Notes:

## Results analysis stage

|  |              |
|--|--------------|
| Analysis stage                                       | Final        |
| Date of interim/final analysis                       | 09 June 2022 |
| Is this the analysis of the primary completion data? | No           |

|                                  |              |
|----------------------------------|--------------|
| Global end of trial reached?     | Yes          |
| Global end of trial date         | 28 June 2022 |
| Was the trial ended prematurely? | Yes          |

Notes:

## General information about the trial

Main objective of the trial:

This was a phase 1b, open-label, single dose study in pediatric participants hospitalized due to COVID-19. The purpose of this study was to describe the pharmacokinetic profile of casirivimab+imdevimab when administered as treatment in the pediatric population and to demonstrate that a single intravenous dose of casirivimab+imdevimab was safe and tolerated in these participants.

Protection of trial subjects:

It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory requirements.

Background therapy: -

Evidence for comparator: -

|   |                  |
|---|------------------|
| Actual start date of recruitment                          | 16 December 2021 |
| Long term follow-up planned                               | No               |
| Independent data monitoring committee (IDMC) involvement? | Yes              |

Notes:

## Population of trial subjects

### Subjects enrolled per country

|                                      |                  |
|--------------------------------------|------------------|
| Country: Number of subjects enrolled | United States: 2 |
| Worldwide total number of subjects   | 2                |
| EEA total number of subjects         | 0                |

Notes:

### Subjects enrolled per age group

|   |   |
|---|---|
| In utero                                  | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days)                      | 0 |
| Infants and toddlers (28 days-23 months)  | 1 |
| Children (2-11 years)                     | 0 |
| Adolescents (12-17 years)                 | 1 |
| Adults (18-64 years)                      | 0 |
| From 65 to 84 years                       | 0 |

|                   |   |
|-------------------|---|
| 85 years and over | 0 |
|-------------------|---|

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

As a result of the early termination, only 2 participants were enrolled in this study.

### Period 1

|                              |                          |
|------------------------------|--------------------------|
| Period 1 title               | Overall (overall period) |
| Is this the baseline period? | Yes                      |
| Allocation method            | Randomised - controlled  |
| Blinding used                | Not blinded              |

### Arms

|                              |   |
|------------------------------|---|
| Are arms mutually exclusive? | Yes   |
| <b>Arm title</b>             | REGN10933+REGN10987 2400mg IV weight-based equivalent |

Arm description: -

|  |                        |
|--|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | REGN10933+REGN10987    |
| Investigational medicinal product code |                        |
| Other name                             | casirivimab+imdevimab  |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intravenous use        |

Dosage and administration details:

Casirivimab+imdevimab drug products were supplied as liquid solutions for IV administration. A weight-based dose was intravenously administered to participants.

|                  |   |
|------------------|---|
| <b>Arm title</b> | REGN10933+REGN10987 8000mg IV weight-based equivalent |
|------------------|---|

Arm description: -

|  |                        |
|--|------------------------|
| Arm type                               | Experimental           |
| Investigational medicinal product name | REGN10933+REGN10987    |
| Investigational medicinal product code |                        |
| Other name                             | casirivimab+imdevimab  |
| Pharmaceutical forms                   | Solution for injection |
| Routes of administration               | Intravenous use        |

Dosage and administration details:

Casirivimab+imdevimab drug products were supplied as liquid solutions for IV administration. A weight-based dose was intravenously administered to participants.

| <b>Number of subjects in period 1</b> | REGN10933+REGN10987 2400mg IV weight-based equivalent | REGN10933+REGN10987 8000mg IV weight-based equivalent |
|---------------------------------------|---|---|
| Started                               | 1   | 1   |
| Completed                             | 1   | 1   |



## Baseline characteristics

### Reporting groups

|                                |   |
|--------------------------------|---|
| Reporting group title          | REGN10933+REGN10987 2400mg IV weight-based equivalent |
| Reporting group description: - |   |
| Reporting group title          | REGN10933+REGN10987 8000mg IV weight-based equivalent |
| Reporting group description: - |   |

| Reporting group values                             | REGN10933+REGN10987 2400mg IV weight-based equivalent | REGN10933+REGN10987 8000mg IV weight-based equivalent | Total |
|--|---|---|-------|
| Number of subjects                                 | 1   | 1   | 2     |
| Age Categorical<br>Units: Subjects                 |   |   |       |
| In utero   | 0   | 0   | 0     |
| Preterm newborn infants (gestational age < 37 wks) | 0   | 0   | 0     |
| Newborns (0-27 days)                               | 0   | 0   | 0     |
| Infants and toddlers (28 days-23 months)           | 1   | 0   | 1     |
| Children (2-11 years)                              | 0   | 0   | 0     |
| Adolescents (12-17 years)                          | 0   | 1   | 1     |
| Adults (18-64 years)                               | 0   | 0   | 0     |
| From 65-84 years                                   | 0   | 0   | 0     |
| 85 years and over                                  | 0   | 0   | 0     |
| Gender Categorical<br>Units: Subjects              |   |   |       |
| Female   | 1   | 0   | 1     |
| Male   | 0   | 1   | 1     |

## End points

### End points reporting groups

|                                |   |
|--------------------------------|---|
| Reporting group title          | REGN10933+REGN10987 2400mg IV weight-based equivalent |
| Reporting group description: - |   |
| Reporting group title          | REGN10933+REGN10987 8000mg IV weight-based equivalent |
| Reporting group description: - |   |

### Primary: Proportion of participants with treatment-emergent serious adverse events (SAEs)

|                 |   |
|-----------------|---|
| End point title | Proportion of participants with treatment-emergent serious adverse events (SAEs) <sup>[1]</sup> |
|-----------------|---|

End point description: -

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Through Day 29

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical Analysis was not performed for this endpoint

| End point values            | REGN10933+REGN10987 2400mg IV weight-based equivalent | REGN10933+REGN10987 8000mg IV weight-based equivalent |  |  |
|-----------------------------|---|---|--|--|
| Subject group type          | Reporting group                                       | Reporting group                                       |  |  |
| Number of subjects analysed | 1   | 1   |  |  |
| Units: Participants         | 0   | 0   |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Proportion of participants with infusion-related reactions

|                 |   |
|-----------------|---|
| End point title | Proportion of participants with infusion-related reactions <sup>[2]</sup> |
|-----------------|---|

End point description: -

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Through Day 4

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical Analysis was not performed for this endpoint

| End point values            | REGN10933+R<br>EGN10987<br>2400mg IV<br>weight-based<br>equivalent | REGN10933+R<br>EGN10987<br>8000mg IV<br>weight-based<br>equivalent |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed | 1  | 1  |  |  |
| Units: participants         | 0  | 0  |  |  |

### Statistical analyses

No statistical analyses for this end point

### Primary: Proportion of participants with hypersensitivity reactions

|                 |   |
|-----------------|---|
| End point title | Proportion of participants with hypersensitivity reactions <sup>[3]</sup> |
|-----------------|---|

End point description:

|                |         |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Through Day 29

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Statistical Analysis was not performed for this endpoint

| End point values            | REGN10933+R<br>EGN10987<br>2400mg IV<br>weight-based<br>equivalent | REGN10933+R<br>EGN10987<br>8000mg IV<br>weight-based<br>equivalent |  |  |
|-----------------------------|--|--|--|--|
| Subject group type          | Reporting group  | Reporting group  |  |  |
| Number of subjects analysed | 1  | 1  |  |  |
| Units: participants         | 0  | 0  |  |  |

### Statistical analyses

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From first dose to end of study, approximately 6 months.

|                 |            |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

### Dictionary used

|                 |        |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

|                    |      |
|--------------------|------|
| Dictionary version | 25.0 |
|--------------------|------|

### Reporting groups

|                       |   |
|-----------------------|---|
| Reporting group title | REGN10933+REGN10987 8000mg IV weight-based equivalent |
|-----------------------|---|

Reporting group description:

REGN10933+REGN10987 8000mg intravenous (IV) weight-based equivalent

|                       |   |
|-----------------------|---|
| Reporting group title | REGN10933+REGN10987 2400mg IV weight-based equivalent |
|-----------------------|---|

Reporting group description:

REGN10933+REGN10987 2400mg intravenous (IV) weight-based equivalent

| Serious adverse events                            | REGN10933+REGN10987 8000mg IV weight-based equivalent | REGN10933+REGN10987 2400mg IV weight-based equivalent |  |
|---|---|---|--|
| Total subjects affected by serious adverse events |   |   |  |
| subjects affected / exposed                       | 0 / 1 (0.00%)   | 0 / 1 (0.00%)   |  |
| number of deaths (all causes)                     | 0   | 0   |  |
| number of deaths resulting from adverse events    |   |   |  |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events                            | REGN10933+REGN10987 8000mg IV weight-based equivalent | REGN10933+REGN10987 2400mg IV weight-based equivalent |  |
|---|---|---|--|
| Total subjects affected by non-serious adverse events |   |   |  |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 1 / 1 (100.00%)                                       |  |
| Infections and infestations                           |   |   |  |
| Otitis media  |   |   |  |
| subjects affected / exposed                           | 0 / 1 (0.00%)   | 1 / 1 (100.00%)                                       |  |
| occurrences (all)                                     | 0   | 1   |  |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? Yes

| Date             | Interruption   | Restart date |
|------------------|--|--------------|
| 22 December 2021 | Participant enrollment was paused. No further participants were enrolled, however, the two enrolled participants continued until the end of study. | -            |

Notes:

### Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

|   |
|---|
| This study was halted prematurely due to emerging SARS-CoV-2 variants impacting susceptibility to study drug. |
|---|

Notes: